Black Diamond Therapeutics, Inc. (BDTX) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
BDTX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Black Diamond Therapeutics, Inc. (BDTX) trades at a price-to-earnings ratio of 7.2x, with a stock price of $2.82 and trailing twelve-month earnings per share of $0.38.
The current P/E is 54% below its 5-year average of 15.7x. Over the past five years, BDTX's P/E has ranged from a low of 10.5x to a high of 25.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.2x, BDTX trades at a 67% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, BDTX trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BDTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BDTX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 7.8Lowest | -Best | +5167%Best | |
| $7B | 146.2 | -Best | +287% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
BDTX Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $3.79 | $0.36 | 10.5x | -33% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $2.48 | $0.23 | 10.8x | -31% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $1.55 | $0.06 | 25.8x | +64% |
Average P/E for displayed period: 15.7x
See BDTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BDTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BDTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBDTX — Frequently Asked Questions
Quick answers to the most common questions about buying BDTX stock.
Is BDTX stock overvalued or undervalued?
BDTX trades at 7.2x P/E, below its 5-year average of 15.7x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does BDTX's valuation compare to peers?
Black Diamond Therapeutics, Inc. P/E of 7.2x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is BDTX's PEG ratio?
BDTX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.